Preview

Obstetrics, Gynecology and Reproduction

Advanced search

ABILITIES OF THERAPY FOR DYSHORMONAL MAMMARY GLAND PATHOLOGY IN FEMALES WITH GYNECOLOGICAL DISEASES

Full Text:

Abstract

Benign alterations of mammary glands are the most common diseases in women. The fibrocystic breast disease (FCBD) is the most common benign disease of mammary glands at that. One of the etiologic factors of breast disease occurrence are believed to be conditions which are due to reduced progesterone level at the backdrop of excess estrogen level, which brings about proliferation of mammary gland tissue and disorders of its receptor apparatus. The most characteristic clinical manifestations of FCBD are breast tenderness (mastodynia) with possible irradiation, sensation of breast size enlargement, breast engorgement and swelling. Often, the mastopathy symptoms are combined with pre menstrual syndrome. Methods of treatment of mammary gland diseases are selected individually, taking into account factors affecting the pathological condition. Currently, the plant derived medications are widely used for treatment, such as Mamoclam andMastodion, as well as a transdermal preparation Progestogel. In the FCBD females on a long term COC treatment an improved mammary gland condition is observed. This treatment effect is due to normalization of hormonal parameters and menstrual period, reduction of rate of functional ovarian cysts' formation and frequency of inflammatory genital diseases.

About the Author

T. V. Ovsyannikova
I.M. Sechenov Moscow Medical Academy
Russian Federation
D. Med. Sci., professor Department of Obstetrics and Gynecology


References

1. Асриян Я.Б., Овсянникова Т.В., Озерова О.Е. Особенности состояния молочных желез при эндокринных формах бесплодия у женщинУ/Проблемы репродукции. 2009 Т.15. №1 С.100 103.

2. Бурдина Л.М. Мастодинон и его роль в лечении доброкачественных заболеваний молочных желез. -Маммология, 1998, с. 45 47.

3. Корнеева И.Е. Диагностика и лечение бесплодия у пациенток с функциональной гиперполактиенмией

4. Макарова И.И., Асриян Я.Б. Принципы терапии предменструального синдрома.//Сбор ник «Репродуктивное здоровье семьи: Материалы Второго Международного конгресса по репродуктивной медицине». -Москва, 2008.-С 209 210.

5. Мустафин Ч.Н., Кузнецова С.В.//Дисгормональные болезни молочной железы. Москва, 2009,С. 127

6. Овсянникова Т.В., Асриян Я.Б., Ардус Ф.А. Возможности терапии дисгормональной патологии молочных желез у женщин с гинекологическими заболеваниями//Русский Медицинский журнал. 2008 Т.16. №17 СЮ 64 10 67.

7. Практическая маммология//под. ред. М.И. Давыдова, В.П. Летягина. Практическая медицина, 2007, стр. 8 53.

8. Филлипов О.С.//Доброкачественные заболевания молочных желез. -МЕДпресс, Москва, 2008, С.106.

9. Beral V. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003, v. 362, p.1160 1167.112 10.

10. Greiser С.М., Greiser E.M., Doren M. Menopausal hormone therapy and risk of breast cancer: a meta analysis of epidemiological studies and randomized controlled trials. Hum.Reprod. Update. 2005, v.11, p.561-573.


For citation:


Ovsyannikova T.V. ABILITIES OF THERAPY FOR DYSHORMONAL MAMMARY GLAND PATHOLOGY IN FEMALES WITH GYNECOLOGICAL DISEASES. Obstetrics, Gynecology and Reproduction. 2010;4(2):28-32. (In Russ.)

Views: 170


ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)